S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.10
+360.20
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
18.23
+1.55
+9.29%
CNTB · Connect Biopharma Holdings Limited Ordinary Shares
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Connect Biopharma Holdings Ltd (CNTB)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$0.80
-0.08
(-9.18%)
● At close: October 21 at 4:00:00 PM EDT
$0.80
+0.00
(+0.31%)
Overnight:
3:14:55 AM EDT
DAY'S RANGE
$0.80
$0.79
$0.86
52-WEEK RANGE
$0.80
$0.85
$3.82
What's happening
- CNTB is down 9.18% today, trading at $0.80. — Live quote
- It's trading within 3% of its 52-week low ($0.85). (Finnhub fundamentals)
- Volume today (11,688) is well below its 3-month average of 2,939,390. (Finnhub fundamentals)
- Reports earnings on 2026-11-10, 19 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.27 actual vs. $-0.32 estimated (+16.0%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 5
Buy 8
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (14 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
CNTB
-68.96%
vs S&P 500
-81.74%
1-YEAR RETURN
CNTB
-50.27%
vs S&P 500
-64.83%
6-MONTH RETURN
CNTB
-70.73%
3-MONTH RETURN
CNTB
-60.40%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.27
Est. $-0.32
BEAT +16.0%
2026-04-26 (Q1 2026)
$-0.34
Est. $-0.23
MISS -50.2%
2026-01-26 (Q4 2025)
$-0.27
Est. $-0.21
MISS -29.8%
2025-10-26 (Q3 2025)
$-0.31
Est. $-1.01
BEAT +69.4%
Valuation Measures & Ratios
Enterprise Value4$28.1M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)18.66
Price / Book75.58
EV4 / Revenue9.52
EV4 / EBITDA—
Profit Margin-1824.65%
Operating Margin-1858.72%
Return on Equity (ROE8)-165.41%
Return on Assets (ROA9)-121.58%
Avg Volume (3M)2,939,390
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $101.4M | $49.4M | $2.8M | $1.9M | $1.1M |
| P/E | -1.52 | -0.83 | -0.05 | -0.09 | -0.07 |
| Price/Sales | 33.77 | 212.22 | 2.18 | 0.08 | — |
| Price/Book | 3.77 | 1.16 | 0.05 | 0.03 | 0.01 |
| EV/Revenue | 24.77 | 14.65 | -27.32 | -1.52 | — |
| EV/EBITDA | -1.10 | -0.06 | 0.63 | — | — |
| ROE | -248.62% | -140.23% | -96.16% | -29.72% | -20.50% |
| ROA | -153.62% | -99.51% | -79.05% | -25.63% | -18.34% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short3,499,648
Change from Prior Settlement+26.16%
% of Float—
Days to Cover (Short Ratio)1.00
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 5666.7% on the provider's reported measure. Finnhub fundamentals ↗
- Latest SEC filing is Form 4, filed 2026-10-01; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -1824.7%. Finnhub fundamentals ↗
- Trailing 52-week price return is -50.3%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on CNTB
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.8M | $169.0K | $16.0K | $48.0K | $0 | $1.2M | $24.1M | — |
| Operating income | -$17.6M | -$19.6M | -$17.7M | -$13.4M | -$11.4M | -$13.8M | $13.6M | -$12.6M |
| Net income | -$17.3M | -$19.4M | -$17.2M | -$12.9M | -$10.3M | -$12.9M | $14.8M | -$8.7M |
| EPS (diluted) | $-0.27 | $-0.34 | $-0.31 | $-0.23 | $-0.19 | $-0.23 | $0.27 | $-0.16 |
| EPS (basic) | $-0.27 | $-0.34 | $-0.31 | $-0.23 | $-0.19 | $-0.23 | $0.27 | $-0.16 |
| Operating margin | -$636 | -$11.6K | -$110.5K | -$28.0K | — | -$1.1K | $57 | — |
| Net margin | -$624 | -$11.5K | -$107.5K | -$26.9K | — | -$1.1K | $62 | — |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $43.5M | $60.1M | $56.1M | $67.4M | $82.7M | $92.7M | $101.3M | — |
| Total liabilities | $16.6M | $17.4M | $14.1M | $12.0M | $11.4M | $9.8M | $9.1M | — |
| Stockholders' equity | $26.9M | $42.6M | $42.0M | $55.4M | $71.3M | $82.9M | $92.2M | $100.6M |
| Total current assets | $38.6M | $55.0M | $50.9M | $62.6M | $77.8M | $87.8M | $97.0M | — |
| Total current liabilities | $16.3M | $17.0M | $13.6M | $11.4M | $10.7M | $8.6M | $8.5M | — |
| Cash & equivalents | $27.0M | $46.0M | $38.3M | $37.8M | $40.6M | $47.7M | $78.2M | — |
| Marketable securities (current) | $4.5M | $0 | $6.0M | $16.9M | $31.1M | $36.3M | $15.5M | — |
| Accounts receivable | $2.9M | $0 | $13.0K | $17.0K | $0 | $8.0K | $789.0K | — |
| Other current assets | — | — | — | — | $228.0K | $65.0K | $53.0K | — |
| Property, plant & equipment | $3.6M | $3.7M | $3.8M | $3.9M | $4.1M | $3.9M | $4.0M | — |
| Intangible assets | $42.0K | $43.0K | $45.0K | $47.0K | $48.0K | $50.0K | $53.0K | — |
| Other non-current assets | $646.0K | $646.0K | $646.0K | $45.0K | $45.0K | $45.0K | $33.0K | — |
| Accounts payable | $2.0M | $4.3M | $2.0M | $2.0M | $2.3M | $817.0K | $342.0K | — |
| Accrued liabilities | $13.9M | $12.3M | $11.2M | $8.9M | $7.9M | $7.2M | $7.8M | — |
| Deferred revenue (current) | $0 | $0 | $167.0K | $165.0K | $164.0K | $164.0K | $164.0K | — |
| Other non-current liabilities | $107.0K | $111.0K | $114.0K | $118.0K | $122.0K | $627.0K | $632.0K | — |
| Common stock & paid-in capital | $11.0K | $11.0K | $10.0K | $10.0K | $10.0K | $10.0K | $10.0K | — |
| Retained earnings | -$437.5M | -$420.2M | -$400.8M | -$385.7M | -$368.5M | -$355.6M | -$345.4M | — |
| Accumulated other comprehensive income (loss) | -$962.0K | -$1.1M | -$1.2M | -$1.3M | -$1.4M | -$1.6M | -$1.7M | — |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$15.9M | -$16.0M | -$11.2M | -$17.4M | -$12.6M | -$10.0M | -$2.3M | -$13.0M |
| Investing cash flow | -$4.5M | $6.0M | $11.0M | $14.3M | $5.1M | -$20.6M | -$15.8M | -$147.0K |
| Financing cash flow | $1.3M | $17.6M | $715.0K | $215.0K | $161.0K | $2.0K | $106.0K | $0 |
| Free cash flow | -$15.9M | -$16.0M | -$11.3M | -$17.4M | -$12.9M | -$10.0M | -$2.6M | -$13.2M |
| Capital expenditures | $0 | $0 | $16.0K | $34.0K | $303.0K | $81.0K | $313.0K | $147.0K |
| Depreciation & amortization | $161.0K | $164.0K | $181.0K | $179.0K | $171.0K | $173.0K | $158.0K | $176.0K |
| Share-based compensation | $1.3M | $1.2M | $917.0K | $916.0K | $951.0K | $942.0K | $1.4M | $2.0M |
| Change in accounts receivable | $2.9M | -$13.0K | -$4.0K | $17.0K | -$8.0K | -$781.0K | -$4.2M | $5.0M |
| Change in accounts payable | -$2.3M | $2.3M | -$30.0K | -$300.0K | $1.5M | $475.0K | -$41.0K | -$147.0K |
| Purchases of investments | $4.5M | $0 | $0 | $0 | $7.9M | $22.6M | $15.5M | $0 |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 |
|---|---|---|---|
| Revenue | $64.0K | $26.0M | $0 |
| Operating income | -$58.1M | -$22.5M | -$69.1M |
| Net income | -$55.5M | -$15.6M | -$62.1M |
| EPS (diluted) | $-1.00 | $-0.28 | $-1.13 |
| EPS (basic) | $-1.00 | $-0.28 | $-1.13 |
| Operating margin | -$90.7K | -$86 | — |
| Net margin | -$86.7K | -$60 | — |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 |
|---|---|---|---|---|
| Total assets | $56.1M | $101.3M | $127.4M | — |
| Total liabilities | $14.1M | $9.1M | $25.9M | — |
| Stockholders' equity | $42.0M | $92.2M | $101.5M | $158.4M |
| Total current assets | $50.9M | $97.0M | $122.6M | — |
| Total current liabilities | $13.6M | $8.5M | $25.3M | — |
| Cash & equivalents | $38.3M | $78.2M | $105.7M | — |
| Marketable securities (current) | $6.0M | $15.5M | $12.6M | — |
| Accounts receivable | $13.0K | $789.0K | $0 | — |
| Other current assets | — | $53.0K | $54.0K | — |
| Property, plant & equipment | $3.8M | $4.0M | $4.3M | — |
| Intangible assets | $45.0K | $53.0K | $62.0K | — |
| Other non-current assets | $646.0K | $33.0K | $24.0K | — |
| Accounts payable | $2.0M | $342.0K | $2.2M | — |
| Accrued liabilities | $11.2M | $7.8M | $9.5M | — |
| Deferred revenue (current) | $167.0K | $164.0K | $13.3M | — |
| Other non-current liabilities | $114.0K | $632.0K | — | — |
| Common stock & paid-in capital | $10.0K | $10.0K | $10.0K | — |
| Retained earnings | -$400.8M | -$345.4M | -$329.7M | — |
| Accumulated other comprehensive income (loss) | -$1.2M | -$1.7M | -$1.0M | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 |
|---|---|---|---|
| Operating cash flow | -$51.2M | -$23.6M | -$47.7M |
| Investing cash flow | $9.8M | -$3.5M | $75.0M |
| Financing cash flow | $1.1M | $227.0K | $45.0K |
| Free cash flow | -$51.6M | -$24.4M | -$47.8M |
| Capital expenditures | $434.0K | $750.0K | $81.0K |
| Depreciation & amortization | $704.0K | $660.0K | $720.0K |
| Share-based compensation | $3.7M | $6.7M | $5.4M |
| Change in accounts receivable | -$776.0K | $789.0K | $0 |
| Change in accounts payable | $1.6M | -$1.9M | -$1.1M |
| Purchases of investments | $30.5M | $15.5M | $31.0M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding CNTB as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 8 most recent filings · covers 2026-03-31 to 2026-09-30
Recent transactions
- Insiders have net bought 150,000 shares over the last 182 days, across 1 purchase and 0 sales.
- Most recent: Xanthopoulos Kleanthis Gabriel (Director) — Grant / award of 5,000 shares on 2026-09-30.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)150,000 sh(1 txns)
Sales (open market)0 sh(0 txns)
Net Shares+150,000
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Xanthopoulos Kleanthis Gabriel | Director | Grant / award | 2026-09-30 | 5,000 |
| LIU JEAN I | Director | Grant / award | 2026-09-30 | 8,984 |
| Huang James | Reporting person | Open market purchase | 2026-05-29 | 150,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-30 | Xanthopoulos Kleanthis Gabriel | Director | Grant / award | 5,000 | $0.00 |
| 2026-09-30 | LIU JEAN I | Director | Grant / award | 8,984 | $0.00 |
| 2026-06-30 | Xanthopoulos Kleanthis Gabriel | Director | Grant / award | 3,738 | $0.00 |
| 2026-06-30 | LIU JEAN I | Director | Grant / award | 6,718 | $0.00 |
| 2026-05-29 | Huang James | Reporting person | Open market purchase | 150,000 | $2.48 |
| 2026-03-31 | Xanthopoulos Kleanthis Gabriel | Director | Grant / award | 2,816 | $0.00 |
| 2026-03-31 | LIU JEAN I | Director | Grant / award | 5,061 | $0.00 |
| 2026-03-31 | Huang James | Reporting person | Open market purchase | 1,160,000 | $3.45 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 06:30 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-01 | 4 | 2026-09-30 | View on SEC.gov → |
| 2026-10-01 | 4 | 2026-09-30 | View on SEC.gov → |
| 2026-09-30 | 8-K | 2026-09-30 | View on SEC.gov → |
| 2026-09-15 | 8-K | 2026-09-15 | View on SEC.gov → |
| 2026-08-12 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-12 | 8-K | 2026-08-12 | View on SEC.gov → |
| 2026-07-01 | 4 | 2026-06-30 | View on SEC.gov → |
| 2026-07-01 | 4 | 2026-06-30 | View on SEC.gov → |
| 2026-06-02 | 4 | 2026-05-29 | View on SEC.gov → |
| 2026-05-12 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-05-12 | 8-K | 2026-05-12 | View on SEC.gov → |
| 2026-04-23 | 8-K | 2026-04-23 | View on SEC.gov → |
Recent news
Headlines about CNTB (Connect Biopharma Holdings Limited Ordinary Shares). Links open the publisher — we don’t host full articles.
-
Here's Why Connect Biopharma Holdings (CNTB) Could be Great Choice for a Bottom Fisher
Yahoo Finance · 2026-10-19 -
Connect Biopharma COPD Study Shows 81% Cut in Treatment Failures
Yahoo Finance · 2026-10-04 -
Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Seabreeze STAT Study Evaluating Rademikibart for COPD Exacerbations - Slideshow
Seeking Alpha · 2026-09-30 -
Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Seabreeze STAT Study Evaluating Rademikibart for COPD Exacerbations Transcript
Seeking Alpha · 2026-09-30 -
Connect Biopharma Reports Positive Phase 2 Rademikibart COPD Data, Plans FDA Talks on Phase 3 Program
Yahoo Finance · 2026-09-30 -
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation
Yahoo Finance · 2026-09-30 -
Connect Biopharma (CNTB) Misses Key Asthma Trial Goal. Can its Drug Still Move Forward?
Yahoo Finance · 2026-09-22 -
Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Rademikibart Phase 2 Study for Acute Asthma Exacerbations Transcript
Seeking Alpha · 2026-09-16
No headlines in this category right now — try “All”.